215 related articles for article (PubMed ID: 22884988)
1. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
[TBL] [Abstract][Full Text] [Related]
2. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
5. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
6. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.
Liu LZ; Ma T; Zhou J; Long Hu Z; Jun Zhang X; Zhen Zhang H; Zeng M; Liu J; Li L; Jiang Y; Zou Z; Wang F; Zhang L; Xu J; Wang J; Xiao F; Fang X; Zou H; Efanov AM; Thomas MK; Lin HV; Chen J
Bioorg Med Chem Lett; 2020 Mar; 30(5):126857. PubMed ID: 31982234
[TBL] [Abstract][Full Text] [Related]
7. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
9. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
[TBL] [Abstract][Full Text] [Related]
10. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
13. Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents.
Shah K; Patel D; Jadav P; Sheikh M; Sairam KV; Joharapurkar A; Jain MR; Bahekar R
Bioorg Med Chem Lett; 2012 Sep; 22(18):5857-62. PubMed ID: 22917520
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
15. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Feb; 29(3):373-379. PubMed ID: 30587450
[TBL] [Abstract][Full Text] [Related]
16. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
Maruyama T; Seki N; Onda K; Suzuki T; Kawazoe S; Hayakawa M; Matsui T; Takasu T; Ohta M
Bioorg Med Chem; 2009 Aug; 17(15):5510-9. PubMed ID: 19581100
[TBL] [Abstract][Full Text] [Related]
18. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
19. Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Sinz C; Chang J; Lins AR; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Mock S; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7131-6. PubMed ID: 22001094
[TBL] [Abstract][Full Text] [Related]
20. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
